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ABSTRACT: The design of proteolysis-targeting chimeras
(PROTACs) is a powerful small-molecule approach for
inducing protein degradation. PROTACs conjugate a target
warhead to an E3 ubiquitin ligase ligand via a linker. Here we
examined the impact of derivatizing two diﬀerent BET
bromodomain inhibitors, triazolodiazepine JQ1 and the more
potent tetrahydroquinoline I-BET726, via distinct exit vectors,
using diﬀerent polyethylene glycol linkers to VHL ligand
VH032. Triazolodiazepine PROTACs exhibited positive
cooperativities of ternary complex formation and were more potent degraders than tetrahydroquinoline compounds, which
showed negative cooperativities instead. Marked dependency on linker length was observed for BET-degrading and cMyc-driven
antiproliferative activities in acute myeloid leukemia cell lines. This work exempliﬁes as a cautionary tale how a more potent
inhibitor does not necessarily generate more potent PROTACs and underscores the key roles played by the conjugation. The
provided insights and framework for structure−activity relationships of bivalent degraders are anticipated to have wide future
applicability.
■ INTRODUCTION
Targeted protein degradation by exploiting the ubiquitin
proteasome system has recently emerged as a new modality
of intervention for medicinal chemistry.1−3 One approach to
induce protein degradation is to design heterobifunctional
molecules called proteolysis-targeting chimeras (also known as
PROTACs) which comprise a ligand binding an E3 ubiquitin
ligase conjugated to a ligand binding the target protein.4,5 First
introduced by Crews and Deshaies in 2001 (ref 6), develop-
ments of the technology over the following decade were in
large part hampered by poor druglikeness of the early
generation compounds that typically incorporated peptidic
binders for E3 ligases.6,7 Recently discovered high-aﬃnity small
molecules for the Cullin RING E3 ubiquitin ligases (CRLs),8 in
particular against von Hippel−Lindau (VHL, e.g., 1 (VH032),
Chart 1)9−11 and cereblon (CRBN, e.g., 2 (pomalidomide),
Chart 1)12−15 greatly contributed to full realization of the
technology’s potential. As a result of these developments, we
and others recently reported potent activities and speciﬁcity in
cells and in vivo of both VHL-based5,16−20 and CRBN-
based18,20−25 PROTACs against several targets, including the
bromodomain and extra-terminal (BET) proteins Brd2, Brd3,
and Brd4.16,19,21,22 BET proteins are particularly attractive
targets, with a dozen of BET inhibitors from diﬀerent
scaﬀolds,26,27 that are in >20 clinical trials against a variety of
diseases, mainly solid and hematological cancers including acute
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CRBN (2) and BET Inhibitors 3 (JQ1)34 and 4 (I-
BET726)36
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myeloid leukemia (AML) and mixed lineage leukemia
(MLL)28,29 as well as NUT-midline carcinomas.30 BET-
targeting PROTACs could provide advantageous therapeutic
proﬁles over BET inhibitors.19 In addition to their therapeutic
potential, BET-targeting PROTACs provide useful chemical
tools for posttranslational protein knockdown. The acute,
profound, and reversible eﬀect of this class of compounds make
it an alternative and advantageous approach to genetic
knockdowns to study the function of BET proteins in
physiological and disease cellular state.
One potential advantage of transforming inhibitors into
degraders using the PROTAC approach is that removal of the
entire protein is expected to be mechanistically diﬀerent from
blockade of a single domain interaction with an inhibitor and to
more closely phenocopy genetic downregulation. This
limitation is exempliﬁed by small-molecule inhibitors of the
bromodomain of SMARCA2 and SMARCA4, which fail to
display the antiproliferative phenotype expected based on
genetic protein knockdown.31 A second advantage of ligand
directed protein degradation is the potential to enhance
selectivity of target modulation over and above the binary
target engagement selectivity of the constitutive inhibitor.5,16
Selective targeting of a single BET protein while sparing its
paralogs would allow to better decipher their individual
physiological roles.32 This is particularly relevant given
traditional genetic techniques have proven challenging,
exempliﬁed by the embryonic lethality of BET gene knock-
outs.30 While selective inhibition of BET bromodomains can be
achieved using allele-selective bump-and-hole approaches,33
single-point mutations need to be introduced ideally using
isogenic knock-ins to enable selective target inhibition.
We previously reported VHL-targeting PROTAC com-
pounds 6 (MZ1) and analogue 7 (MZ2) (Chart 2, see ref
16) that induced preferential depletion of a single BET
member, Brd4, over Brd2 and Brd3, despite binding the
diﬀerent BET bromodomains with comparable aﬃnities.16 Our
recent work disclosing the crystal structure of VHL−6−Brd4
ternary complex, the ﬁrst crystal structure of a PROTAC bound
to both target protein and E3 ligase, showed how PROTAC 6
folds into itself to allow the two proteins to form productive
interactions.5 Our discovery provided structural insights into
ligand-induced protein−protein interactions driving coopera-
tive and preferential formation of ternary complexes as a basis
for eﬀective target degradation.5 This realization has important
implications for PROTACs, as it demonstrates an added layer
of target depletion selectivity through PROTAC-induced
interactions between the target and the ligase, and supports
important roles for the derivatization mode of the two warhead
ligands via the linker. All BET-degrading PROTACs reported
so far by us and others16,19,21,22 are based on the pan-selective
triazolodiazepine-based BET inhibitor 3 (Chart 1).34 However,
while this manuscript was under review, a study has reported
active CRBN-based BET degraders based on an azacarbazole
containing BET inhibitor.35 To interrogate the impact of using
a diﬀerent, more potent BET inhibitor than 3, and of exploring
a diﬀerent vector out of the warhead, on the activity and intra-
BET selectivity proﬁle of BET-targeting PROTACs, we here
report novel VHL-recruiting PROTACs derived from a high-
aﬃnity BET ligand, the tetrahydroquinoline-based BET
inhibitor 4 (Chart 1).36
■ RESULTS AND DISCUSSION
Crystal structures of 4 (Kd for Brd4 tandem bromodomain is 4
nM;36 compare to Kd of 100 nM for 3, ref 34) bound to BET
bromodomains show that the free carboxylic acid of the BET
inhibitor is solvent exposed and is not involved in direct
interactions with the protein (Figure 1b).36,37 We therefore
hypothesized that the carboxylate group could be exploited to
Chart 2. Chemical Structures of VHL-Targeting PROTACs
Based on 4 and 3 Used in This Study and Chemical
Structure of CRBN-Targeting PROTAC 11 (ARV-825)
Figure 1. Co-crystal structures to guide PROTAC linking design. First
bromodomain of Brd4 with bound (a) 3 (green carbons, PDB code
3MXF34) and (b) 4 (cyan carbons, PDB code 4BJX37). Arrows
highlight exit vectors for linking.
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readily conjugate a linker, e.g., via amide bond formation,
without impairing binding to BET bromodomains. Super-
position of the cocrystal structures of 3 and 4 each bound to
the N-terminal bromodomain of Brd4 (Figure 1) additionally
showed that the benzoic acid group of 4 extends in a diﬀerent
direction from the tert-butyl ester group of 3. We therefore
became interested in exploring the tolerance of the PROTAC
approach to diﬀerent exit vectors from BET inhibitor scaﬀolds.
On the basis of this design strategy, 4 was connected to the
terminal acetamide group of VHL ligand 1 (ref 10) to obtain
PROTACs 8 (MZP-61), 9 (MZP-54), and 10 (MZP-55) which
bear a 2-, 3-, and 4-unit PEG linker, respectively, consistent
with 5 (MZ4), 6, and 7 (Chart 2). Cereblon-based compound
11 (Chart 2, ref 22) was also included to provide a ﬁrst direct
comparison with VHL-based PROTACs.
To assess BET degradation activities, compounds were ﬁrst
proﬁled in HeLa cancer cells because these cells are less
susceptible to the cytotoxic eﬀects of BET knockdown or
inhibition (Figure 2 and Figure S1; see full blots in Figure S5).
Representative PROTACs 10 and 7 (each containing a PEG-4
linker unit) induced marked concentration-dependent knock-
down of BET proteins (Figure 2).
Interestingly, tetrahydroquinoline-based compound 10
showed depletion selectivity for Brd4 and Brd3 over Brd2, in
contrast to 7 that is a Brd4-selective degrader (Figure 2).16 A
similar pattern of BET proteins degradation was observed with
PEG-3 linked compounds 9 and 6 (Figure S1c,d,g,h). In
Figure 2. Protein degradation proﬁle of VHL-based BET degraders. HeLa cells were treated for 24 h. Protein levels are shown from one
representative of two biological replicates, visualized by immunoblot (a, c) and quantiﬁed relative to DMSO control (b, d). Intensity values were
quantiﬁed as described in the Experimental Section.
Table 1. ITC Results of Binary and Ternary Complex Formation for PROTACs 5−10 and Brd4BD2 and VCBa
protein in
syringe species in cell Kd (nM) ΔG (kcal·mol−1) ΔH (kcal·mol−1) −TΔS (kcal·mol−1) stoichiometry N α
ΔpKd ±
uncertainty
no. of
replicates
Brd4BD2 8b 3 ± 2 −11.7 ± 0.4 −10.0 ± 0.1 −1.71 ± 0.43 0.804 ± 0.003 1
Brd4BD2 9b 4 ± 2 −11.5 ± 0.3 −9.74 ± 0.10 −1.73 ± 0.30 1.15 ± 0.01 1
Brd4BD2 10 8 ± 4 −11.1 ± 0.3 −10.8 ± 0.05 −0.33 ± 0.38 0.86 ± 0.06 2
Brd4BD2 5 17 ± 2 −10.6 ± 0.06 −11.2 ± 0.04 −0.65 ± 0.47 0.81 ± 0.04 4
Brd4BD2 6 26 ± 2 −10.3 ± 0.04 −11.1 ± 0.8 0.77 ± 0.80 0.91 ± 0.06 3
Brd4BD2 7 27 ± 2 −10.3 ± 0.04 −10.6 ± 0.5 0.31 ± 0.53 0.79 ± 0.03 2
VCB 8b 116 ± 24 −9.46 ± 0.13 −4.07 ± 0.07 −5.39 ± 0.14 1.12 ± 0.01 1
9b 105 ± 24 −9.52 ± 0.13 −6.18 ± 0.12 −3.34 ± 0.18 0.96 ± 0.01 1
10 109 ± 8 −9.50 ± 0.04 −8.01 ± 0.25 −1.50 ± 0.21 0.92 ± 0.15 2
VCB 5 147 ± 24 −9.34 ± 0.10 −5.72 ± 0.47 −3.61 ± 0.37 0.8 ± 0.05 3
6 69 ± 8 −9.77 ± 0.07 −7.76 ± 0.92 −2.02 ± 0.9 0.81 ± 0.07 3
7 73 ± 15 −9.75 ± 0.13 −8.79 ± 0.42 −0.96 ± 0.29 0.76 ± 0.03 2
VCB Brd4BD2−8b 781 ± 60 −8.33 ± 0.05 −7.02 ± 0.11 −1.31 ± 0.12 1.07 ± 0.01 0.2 −0.83 ± 0.10 1
Brd4BD2−9b 228 ± 33 −9.06 ± 0.09 −6.90 ± 0.11 −2.16 ± 0.14 1.44 ± 0.02 0.5 −0.34 ± 0.12 1
Brd4BD2−10 183 ± 29 −9.20 ± 0.10 −7.58 ± 0.05 −1.62 ± 0.15 0.87 ± 0.02 0.6 −0.22 ± 0.08 2
VCB Brd4BD2−5 26 ± 7 −10.4 ± 0.2 −5.36 ± 0.77 −5.05 ± 0.62 0.76 ± 0.06 5.7 0.78 ± 0.16 3
Brd4BD2−6 9 ± 5 −11.1 ± 0.3 −8.47 ± 2.83 −2.59 ± 0.69 0.83 ± 0.04 7.4 0.95 ± 0.29 2
Brd4BD2−7 15 ± 1 −10.7 ± 0.05 −10.6 ± 1.3 −0.07 ± 1.3 0.76 ± 0.07 4.7 0.66 ± 0.10 2
aValues reported are the mean ± SEM, unless speciﬁed otherwise. bErrors are generated by the Origin program and reﬂect the quality of the ﬁt
between the nonlinear least-squares curve and the experimental data.
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contrast, PEG-2 linked PROTACs 5 (Figure S1e,f), and 8
(Figure S1a,b) showed lower activity over all BET proteins.
Similar to tetrahydroquinoline-based PROTACs, 11 showed
some preference for degrading Brd3/4 over Brd2, although all
BET proteins were potently depleted at 100 nM (Figure S1i,j).
Interestingly, treatments with tetrahydroquinoline-based PRO-
TACs 9 and 10 revealed increased levels of BET proteins at the
higher concentration (1−10 μM, Figure S1c,d and Figure 2a,b),
thought to be due to the “hook eﬀect”.4 Brd2 levels even
increased beyond vehicle control level (Figure S1c,d and Figure
2a,b). These eﬀects were largely recapitulated when the
degradation assays were repeated with shorter treatments of 6
h (Figure S2), suggesting that the observed increase in protein
levels is not due to secondary eﬀects at the longer time point.
Control treatments with the parent BET inhibitors 3 and 4 also
led to increased levels of BET proteins (Figure S1k−n).
Marked up-regulation was seen for Brd2 with inhibitor 4
treatment (Figure S1k,l) and for Brd4 long isoform with
inhibitor 3 (Figure S1m,n). Similar up-regulation of Brd4 with
3 were observed in Burkitt’s lymphoma cell lines.22 Together,
the data suggest that tetrahydroquinoline based PROTACs
function more as inhibitors than as degraders at the higher
concentrations. These results underscore the importance to
identify suitable concentrations to dissect eﬀects due to
PROTAC-induced degradation activity from those due to
inhibitory activity and potential cellular feedback mechanisms,
which could compensate pharmacological activity. Nonetheless,
compounds 9 and 10 act as selective degraders of BRD3/4
within appropriate window of concentration (30−100 nM).
The distinctive activity proﬁle of tetrahydroquinoline-based
PROTACs prompted us to compare and contrast thermody-
namics of ternary complex formation equilibria for this class of
PROTACs relative to the triazolodiazepine-based series. We
applied an isothermal titration calorimetry (ITC) based assay
setup that we recently developed to circumvent potential hook-
eﬀects in ternary complex formation and that we used to
characterize thermodynamics and cooperativities for binding of
6 to VHL and diﬀerent BET bromodomains.5 In our previous
work, we showed how 6 forms highly cooperative and stable
complexes between VHL and BET bromodomains and
preferentially with the second bromodomain of Brd4
(Brd4BD2).5 We therefore set out to measure dissociation
constants Kd of binary and ternary complexes formed between
compounds 5−10, the VHL-EloC-EloB protein (VCB), and
Brd4BD2, and the resulting cooperativities (Table 1, see also
Figure S3). At the binary level, the bromodomain warheads of
the PROTACs 8−10 bound the BET bromodomain con-
sistently with higher potency that the corresponding
bromodomain ligand warheads within 5−7, while the VHL
ligand warhead bound VCB with comparable aﬃnities across all
PROTACs (Table 1). However, strikingly, all tetrahydroquino-
line based PROTACs exhibited negative cooperativities of
ternary complex formation, meaning that they bound the ﬁrst
protein more tightly on their own than in the presence of the
second protein (α < 1, where α values are deﬁned as ratio
between binary and ternary Kd values,
5 Table 1; see Figure 3 for
representative binary and ternary titrations of VCB into 10 in
the absence and presence of bromodomain).
Negative cooperativities were conﬁrmed against all six BET
bromodomains, as shown for representative compound 10,
with the Brd2 bromodomains showing the lowest α values
(Table S1). This feature was in stark contrast to the
triazolodiazepine-based series 5−7, which all showed positive
cooperativities (α values of >1, Table 1). The thermodynamic
data highlight an important feature; that is, cooperativities of
PROTACs ternary complex formation do not follow the
binding aﬃnities of the target warheads. Our data exemplify
how PROTACs made from more potent target warhead ligands
can form ternary complexes less productively. It is interesting
that despite being negatively cooperative, compounds 8−10
can still act as eﬀective degraders at low concentration,
underscoring the power of the substoichiometric catalytic
activity of PROTACs. The observation of stronger hook eﬀects
for 8−10 compared to 5−7 in the degradation assays is
however consistent with their negative cooperativity, i.e., with
them behaving more like inhibitors than degraders at higher
concentration. We previously demonstrated the importance of
the ligand-induced protein−protein contacts in dictating the
large positive cooperativity of the VHL−6−Brd4 system.5 It is
therefore likely that the diﬀerent exit vector from the
Figure 3.Measuring cooperativities of ternary complex formation by ITC: (a) VCB titrated into 10 alone; (b) VCB titrated into Brd4BD2−10 binary
complex; (c) VCB titrated into Brd2BD1−10. VCB binds more strongly to 10 alone (Kd = 110 nM) than to Brd4BD2−10 (Kd = 180 nM) or Brd2BD1−
10 (Kd = 330 nM), highlighting negative cooperativity.
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tetrahydroquinoline warhead forces an unfavorable relative
orientation between the E3 ligase and the bromodomain.
Comparing the diﬀerent linker lengths within a given series, it
was found that PEG-3 linked 6 showed the highest
cooperativity among the triazolodiazepine-based series, whereas
PEG-2 linked 8 showed the lowest cooperativity among the
tetrahydroquinoline-based series (Table 1). In both series
overall, short linker proved to be less eﬃcient in forming
ternary complex and inducing protein degradation.
To provide a functional downstream readout of the cellular
activity of BET degraders, we assessed antiproliferative eﬀects
of PROTACs in AML MV4;11 (Figure 4a,b) and HL60 (Figure
S4a,b), as these are well characterized BET-sensitive cell lines
(see full blots in Figure S6). All compounds showed marked
antiproliferative activity in both cell lines. Although some
PROTAC compounds exhibited comparable nanomolar half-
maximal antiproliferative concentrations (pEC50 values) relative
to the constitutive inhibitors alone, the maximal response to
baseline level at the higher concentrations (Emax) of all VHL-
based PROTACs presented here exceeded that of the BET
inhibitors (see Figure 4a,b and Figure S4a,b and values
tabulated in Table 2). This activity is likely owing to the
more profound eﬀect associated with removing the entire
protein compared to blocking an individual binding site, which
leaves other parts and domains of the proteins (e.g., the extra-
terminal ET domain) still functional. PEG-3 and PEG-4 based
Figure 4. Antiproliferative and Myc-suppression activity of BET degraders and inhibitors: (a, b) MV4;11 cells treated with PROTACs and their
corresponding BET targeting ligands for 48 h prior to quantitation of cell viability; (c) half-eﬀective concentrations of BET degraders and
corresponding inhibitors; (d) MV4;11 cells treated for 4 h with BET PROTACs or inhibitors (50 nM) or DMSO control. Protein levels are shown
from one representative of two biological replicates.
Table 2. BET Reduction by PROTACs in HeLa Cells, Antiproliferative Activity, and Brd4/cMyc Reduction in AML Cellsa
pDC50/Dmax (%) in HeLa cells pEC50 Emax (%) Brd4/cMyc depletion (%)
cooperativity
(α)
Brd4
short
Brd4
long Brd3 Brd2 MV4;11 HL60 MV4;11 HL60 MV4;11 HL60 Brd4−BD2
8 6.9/94 6.7/78 6.8/74 −/37 6.24 ± 0.05 6.17 ± 0.03 88.1 ± 1.0 96.6 ± 0.1 11/11 −156/14 0.15
9 8.1/98 7.6/95 7.3/91 −/43 7.31 ± 0.03 6.57 ± 0.02 94.2 ± 0.2 98.3 ± 0.1 87/73 28/50 0.46
10 8.1/95 7.5/93 7.7/92 −/26 7.08 ± 0.05 6.37 ± 0.03 96.4 ± 0.2 98.3 ± 0.1 81/60 22/47 0.59
5 7.0/96 7.0/97 6.5/97 6.2/93 6.75 ± 0.03 5.84 ± 0.06 91.4 ± 0.4 91.4 ± 0.3 51/27 −172/4 5.7
6 8.1/98 8.6/100 7.0/100 7.4/98 7.57 ± 0.03 6.66 ± 0.05 96.1 ± 0.3 92.0 ± 0.4 96/84 82/68 7.4
7 8.4/99 8.0/100 6.5/99 6.7/97 6.91 ± 0.04 5.90 ± 0.05 95.2 ± 0.1 91.7 ± 0.1 93/66 20/23 4.7
11 9.2/97 9.0/100 9.1/98 8.2/83 7.77 ± 0.06 7.46 ± 0.03 83.5 ± 2.3 88.0 ± 0.1 64/70 32/57 nd
4 6.98 ± 0.07 6.69 ± 0.06 73.3 ± 0.6 82.4 ± 4.3 29/67 −157/42
3 6.48 ± 0.09 6.13 ± 0.09 79.1 ± 2.5 73.7 ± 2.5 −29/49 −243/20
aDC50: concentration in molar causing 50% reduction of protein level relative to vehicle control treatment in 24 h. Dmax: maximum reduction of
protein level relative to vehicle control treatment. pEC50 was measured after 48 h treatment. Errors on pEC50 values reﬂect the quality of the curve
ﬁtting. Protein depletion % are for 50 nM treatments (4 h) in MV4;11/HL60. nd: not determined.
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PROTACs proved overall more potent than PEG-2, consistent
with the trends in degradation activities in HeLa and
cooperativities (Figure 4c and Table 2).
To conﬁrm Brd4 degradation and downstream impact on
cMyc levels, we examined protein levels in the same cellular
context following acute pharmacological intervention (4 h
treatments). In each of the two series, PEG-3 and PEG-4 based
PROTACs (6 and 7, 9 and 10) induced superior depletion of
both Brd4 and cMyc over their respective PEG-2 analogues 5
and 8 in both cell lines, at two diﬀerent concentrations (Figure
4d and Figure S4c-e). PROTACs 6 and 7 and 9 also showed
higher depletion of cMyc levels compared to their inhibitor
counterparts, indicating a greater downstream response with
more eﬃcient chemical degraders, while 5 and 8 induce lower
cMyc depletion than the corresponding inhibitors 3 and 4,
respectively (Figure 4d). Together, the results conﬁrmed the
PEG-2 linker length to be too short for optimal PROTAC
activity.
Structure−activity relationschips (SARs) are typically
quantiﬁed by measuring binding or inhibition constants (Kd,
Ki) or inhibitory dose response curves (IC50). Because induced
protein degradation features catalytic depletion of protein levels
over time, diﬀerent parameters are needed to quantify
compounds potency and eﬃcacy. To evaluate SAR in a
quantitative fashion, we evaluted the following: pDC50
(concentration causing 50% reduction of protein level relative
to vehicle) and Dmax (maximum reduction of protein level
relative to vehicle) for HeLa protein degradation responses;
pEC50 (half-maximal eﬀective concentrations) and Emax
(maximal response to baseline level at the highest concen-
trations) from cell viability assays; % reduction of Brd4 and
cMyc levels in AML cell lines; cooperativity (α) of ternary
complex formation with VCB and Brd4BD2 (values reported in
Table 2). To evaluate the main drivers of the observed
antiproliferative eﬀects, we plotted PROTACs pEC50 values
from AML cell viability assays relative to other parameters
(Figure 5). Strong correlation was found between pEC50 in
MV4;11 and pDC50 on the long isoform of Brd4 in HeLa (r
2 =
0.84, Figure 5a). The antiproliferative activities against AML of
BET PROTACs and their parent inhibitors correlated well with
depletion of cellular levels of cMyc in both MV4;11 (r2 = 0.69,
Figure 5b) and HL60 (r2 = 0.62), consistent with AML cells
proliferation being cMyc-driven.38 Overall, PEG-3 linked 6 and
9 were conﬁrmed to be the most eﬀective among the VHL-
based PROTACs, with 6 performing comparably to CRBN-
based PROTAC 11. Importantly, for a given linker length, the
trends conﬁrmed tetrahydroquinoline-based PROTACs to be
less eﬀective degraders than the triazolodiazepine based, despite
the constitutive ligand 4 conﬁrming to be a more potent BET
inhibitor than 3 in these cell lines (Figure 5c).
■ CONCLUSIONS
We describe novel VHL-targeting BET degraders designed
based on a high-aﬃnity tetrahydroquinoline inhibitor and
explore the impact of varying the BET-recruiting scaﬀold and
the linkage vector on PROTAC ternary complex recognition
and cellular activity. Despite being derivatized from a more
potent BET inhibitor, the tetrahydroquinoline based series
showed negative cooperativities of ternary complex formation
and proved to be less eﬀective degraders than the positively
cooperative triazolodiazepine series. These results exemplify
how more potent inhibitors do not necessarily generate more
potent PROTACs and underscore how the ability to strongly
form the ternary complex is critical to the mechanism of action
of bivalent degraders. Side-by-side comparisons demonstrated
remarkable dependency of cellular activity on the linker length,
with a trend of PEG-3 > PEG-4 ≫ PEG-2 observed for both
chemical series, potentially suggesting a “sweet-spot” for
optimal linking within a given E3 ligase−target pair. We also
show how by changing the BET-recruiting warhead and linkage
vector, the intra-BET degradation selectivity proﬁle could be
tuned from Brd4-selective for one series to Brd3/4 selective for
another. Further SAR on either the linker or warhead ligand
and exit vector could optimize potency and selectivity of
degrading the diﬀerent BET proteins. Future work assessing the
impact of varying other parameters, such as the nature of the E3
ligase recruited and the E3 warhead used, is also warranted.
More generally, we provide a framework for establishing future
structure−activity relationships of chemical degraders based on
measurable in vitro parameters that we anticipate will prove
useful to the burgeoning new ﬁeld of inducing protein
degradation with small molecules.
■ EXPERIMENTAL SECTION
A. Chemistry. All chemicals, unless otherwise stated, were
commercially available and used without further puriﬁcation.
Enantiopure (+)-3 and 4 were purchased from Medchemexpress
LLC, Princeton, NJ, USA. (+)-3 was deprotected to the carboxylic acid
form 6H-thieno[3,2-f ][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetic
acid, as previously described.16 11 was synthesized as described
previously.22 6 and 7 were synthesized as described.16 Reactions were
magnetically stirred; commercially available anhydrous solvents were
used. NMR spectra were recorded on a Bruker Ascend 400. Chemical
shifts are quoted in ppm and referenced to the residual solvent signals:
1H δ = 7.26 (CDCl3),
13C δ = 77.16; signal splitting patterns are
described as singlet (s), doublet (d), triplet (t), quartet (q), multiplet
(m), broad (br). Coupling constants (JH−H) are measured in Hz. High
resolution mass spectra (HRMS) were recorded on a Bruker
microTOF. Low resolution MS and analytical HPLC traces were
recorded on an Agilent Technologies 1200 series HPLC connected to
an Agilent Technologies 6130 quadrupole LC−MS, connected to an
Agilent diode array detector. Preparative HPLC was performed on a
Gilson preparative HPLC system with a Waters X-Bridge C18 column
Figure 5. PROTACs’ SAR correlation plots. Anti-AML activities (48 h
treatments) are plotted against (a) HeLa degradation of Brd4 long
isoform (24 h) and (b) reduction in cMyc levels in MV4;11 (4 h).
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(100 mm × 19 mm; 5 μm particle size) and a gradient of 5−95%
acetonitrile in water over 10 min, ﬂow 25 mL/min, with 0.1%
ammonia in the aqueous phase. The purity of all compounds was
analyzed by HPLC−MS (ESI) and was >95%.
General Procedure for Synthesis of VHL Ligand−Linker
Conjugates. The azide-(PEG)n derivatives of compound 1 were
synthesized as previously described.16 Analytical data for azide-(PEG)3
and azide-(PEG)4 were reported previously.16
(2S,4R)-1-((S)-2-(2-(2-(2-Azidoethoxy)ethoxy)acetamido)-
3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)-
benzyl)pyrrolidine-2-carboxamide. The azide-(PEG)2 derivative
was prepared accordingly to the general procedure for synthesis of
VHL ligand−linker conjugates. Obtained 411 mg, colorless oil, 68%
yield. 1H NMR (CDCl3, 400 MHz) δ ppm: 8.68 (s, 1H), 7.38−7.33
(m, 5H), 7.24 (d, J = 8.5 Hz, 1H), 4.75 (t, J = 7.9 Hz, 1H), 4.59−4.54
(m, 2H), 4.48 (d, J = 8.6 Hz, 1H), 4.33 (dd, J = 14.9 Hz, J = 5.2 Hz,
1H), 4.12−4.09 (m, 1H), 4.06−3.96 (m, 2H), 3.70−3.66 (m, 6H),
3.61 (dd, J = 11.4 Hz, J = 3.7 Hz, 1H), 3.41−3.38 (m, 2H), 2.89 (br s,
1H), 2.63−2.58 (m, 1H), 2.52 (s, 3H), 2.13−2.08 (m, 1H), 0.95 (s,
9H). 13C NMR (CDCl3, 101 MHz) δ ppm: 171.6, 170.7, 170.6, 150.7,
138.4, 130.4, 129.7, 128.6, 128.4, 127.6, 71.2, 70.5, 70.3, 70.2, 67.2,
58.5, 57.3, 56.8, 50.7, 43.4, 35.8, 34.9, 26.5, 16.0. MS calcd for
C28H39N7O6S 601.3, found 602.3 [M + H
+].
General Procedure for Synthesis of Final PROTAC Mole-
cules. The azide-(PEG)n derivative of compound 1 (40 μmol) was
dissolved in methanol (5 mL). Catalytic amount of Pd on charcoal
(10%, dry) was added and the reaction mixture stirred under an
atmosphere of hydrogen for 3 h at 25 °C. The reaction mixture was
ﬁltered through a plug of Celite and the resulting solution evaporated
to dryness to obtain the desired amine. The resulting amines (35
μmol, 1.4 equiv) and 4 or the carboxylic acid form of (+)-3 (25 μmol,
1 equiv) were dissolved in DCM (2 mL). HATU (14.3 mg, 37.5 μmol,
1.5 equiv) was added and the pH adjusted to >9 by adding DIPEA
(17.5 μL, 100 μmol, 4 equiv). After stirring the reaction mixture at 25
°C for 18 h the solvent was removed in vacuum. The crude was
puriﬁed by preparative HPLC as described above.
(2S,4R)-1-((S)-2-(tert-Butyl)-14-((S)-4-(4-chlorophenyl)-2,3,9-
trimethyl-6H-thieno[3,2-f ][1,2,4]triazolo[4,3-a][1,4]diazepin-6-
yl)-4,13-dioxo-6,9-dioxa-3,12-diazatetradecanoyl)-4-hydroxy-
N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
(5). White amorphous powder. Yield: 22.2 mg (66%). 1H NMR
(CDCl3, 400 MHz) δ ppm: 8.65 (s, 1H), 8.30−8.25 (m, 2H), 7.63 (d,
J = 10.0 Hz, 1H), 7.36 (d, J = 8.7 Hz, 2H), 7.24 (d, J = 8.3 Hz, 2H),
7.11 (d, J = 8.0 Hz, 2H), 7.02 (d, J = 8.0 Hz, 2H), 4.94−4.86 (m, 2H),
4.63−4.57 (m, 2H), 4.21 (d, J = 5.8 Hz, 2H), 4.07−3.81 (m, 5H),
3.72−3.52 (m, 7H), 3.44 (dd, J = 15.9 Hz, J = 3.0 Hz, 1H), 3.13−3.08
(m, 1H), 2.55 (s, 3H), 2.45 (s, 3H), 2.39−2.35 (m, 4H), 2.27−2.20
(m, 1H), 1.66 (s, 3H), 1.09 (s, 9 H). 13C NMR (CDCl3, 101 MHz) δ
ppm: 172.1, 171.1, 170.6, 170.4, 163.3, 156.2, 150.2, 149.9, 148.4,
138.5, 136.9, 136.7, 131.9, 131.6, 131.4, 131.3, 131.2, 130.2, 130.1, 129,
128.8, 127.7, 71.5, 70.4, 70.3, 69.8, 59.3, 57.5, 56.5, 53.9, 42.7, 39.7,
38.3, 37.2, 36.3, 26.6, 16.2, 14.5, 13.3, 11.8. HRMS m/z calcd for
C46H57N9ClO7S2 expected 957.3505, found 958.3498 [M + H
+].
(2S,4R)-1-((S)-1-(4-((2S,4R)-1-Acetyl-4-((4-chlorophenyl)-
amino)-2-methyl-1,2,3,4-tetrahydroquinolin-6-yl)phenyl)-12-
(tert-butyl)-1,10-dioxo-5,8-dioxa-2,11-diazatridecan-13-oyl)-4-
hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-car-
boxamide (8). White amorphous powder. Yield: 14.5 mg (42%). 1H
NMR (CDCl3, 400 MHz) δ ppm: 8.66 (s, 1H), 7.91 (d, J = 8.2 Hz,
2H), 7.79−7.77 (m, 1H), 7.60−7.50 (m, 5H), 7.32 (d, J = 7.9 Hz,
2H), 7.22 (d, J = 8.1 Hz, 2H), 7.13 (d, J = 9.0 Hz, 2H), 6.63−6.57 (m,
3H), 4.89 (br s, 1H), 4.54−4.37 (m, 4H), 4.22−4.15 (m, 2H), 4.07−
3.90 (m, 3H), 3.81−3.47 (m, 10H), 3.20 (br s, 1H), 2.71−2.64 (m,
1H), 2.50 (s, 3H), 2.38−2.32 (m, 1H), 2.24 (s, 3H), 1.99−1.93 (m,
1H), 1.36−1.25 (m, 1H), 1.18 (d, J = 6.4 Hz, 3H), 0.85 (s, 9H). 13C
NMR (CDCl3, 101 MHz) δ ppm: 171.1, 170.7, 170.6, 169.4, 167.5,
150.3, 148.5, 145.8, 143.4, 137.8, 136.3, 133.4, 131.5, 131.0, 129.5,
129.4, 128.3, 128.1, 126.9, 126.6, 126.0, 122.9, 122.4, 114.5, 77.3, 77.0,
76.7, 71.7, 70.9, 70.7, 70.5, 70.0, 58.8, 57.0, 56.9, 50.5, 43.3, 41.1, 39.8,
36.2, 36.0, 26.4, 23.1, 21.3, 16.1. HRMS m/z calcd for C53H63ClN7O8S
[M + H+] 992.4142, found 992.4091.
(2S,4R)-1-((S)-1-(4-((2S,4R)-1-Acetyl-4-((4-chlorophenyl)-
amino)-2-methyl-1,2,3,4-tetrahydroquinolin-6-yl)phenyl)-15-
(tert-butyl)-1,13-dioxo-5,8,11-trioxa-2,14-diazahexadecan-16-
oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-
2-carboxamide (9). White amorphous powder. Yield: 17.1 mg
(71%). 1H NMR (CDCl3, 400 MHz) δ ppm: 8.66 (s, 1H), 7.80 (d, J =
8.5 Hz, 2H), 7.53−7.48 (m, 4H), 7.36−7.30 (m, 6H), 7.22−7.19 (m,
2H), 7.14 (d, J = 8.7 Hz, 2H), 6.64 (d, J = 8.6 Hz, 2H), 4.88 (br s,
1H), 4.60 (t, J = 7.7 Hz, 1H), 4.52 (d, J = 19.7 Hz, 2H), 4.42 (br s,
1H), 4.34−4.18 (m, 3H), 3.94−3.72 (m, 3H), 3.68−3.51 (m, 14H),
3.21 (br s, 1H), 2.70−2.64 (m, 1H), 2.49 (s, 3H), 2.44−2.36 (m, 1H),
2.22 (s, 3H), 2.05−2.01 (m, 1H), 1.34−1.25 (m, 1H), 1.18 (d, J = 6.3
Hz, 3H), 0.94 (s, 9H). 13C NMR (CDCl3, 101 MHz) δ ppm: 171.1,
170.9, 170.2, 169.5, 167.4, 150.3, 145.8, 143.2, 138.2, 137.7, 136.3,
133.4, 130.9, 129.5, 129.3, 128.1, 127.8, 126.9, 126.5, 125.8, 122.7,
122.6, 114.6, 77.4, 77.0, 76.7, 71.0, 70.4, 70.3, 70.1, 70.0, 69.6, 58.5,
56.9, 56.8, 50.2, 47.6, 43.2, 41.0, 40.0, 36.2, 35.4, 26.4, 23.1, 21.3, 16.1.
HRMS m/z calcd for C55H67ClN7O9S [M + H
+] 1036.4404, found
1036.4356.
(2S,4R)-1-((S)-1-(4-((2S,4R)-1-Acetyl-4-((4-chlorophenyl)-
amino)-2-methyl-1,2,3,4-tetrahydroquinolin-6-yl)phenyl)-18-
(tert-butyl)-1,16-dioxo-5,8,11,14-tetraoxa-2,17-diaza-
nonadecan-19-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)-
benzyl)pyrrolidine-2-carboxamide (10). White amorphous pow-
der. Yield: 14.6 mg (58%). 1H NMR (CDCl3, 400 MHz) δ ppm: 8.66
(s, 1H), 7.84 (d, J = 8.1 Hz, 2H), 7.54−7.49 (m, 4H), 7.36−7.30 (m,
5H), 7.26−7.22 (m, 2H), 7.15−7.12 (m, 3H), 6.62 (d, J = 8.6 Hz,
2H), 4.89 (br s, 1H), 4.69 (t, J = 7.9 Hz, 1H), 4.57−4.46 (m, 3H),
4.33 (dd, J = 5.6, 14.7 Hz, 1H), 4.24−4.15 (m, 2H), 4.00−3.80 (m,
3H), 3.66−3.55 (m, 18H), 3.46 (br s, 1H), 2.69−2.63 (m, 1H), 2.50−
2.44 (m, 4H), 2.22 (s, 3H), 2.10−2.06 (m, 1H), 1.36−1.25 (m, 1H),
1.18 (d, J = 6.2 Hz, 3H), 0.93 (s, 9H). 13C NMR (CDCl3, 101 MHz) δ
ppm: 170.2, 169.5, 167.3, 150.3, 145.8, 143.2, 138.2, 137.8, 136.3,
133.4, 129.5, 129.3, 128.1, 127.8, 126.9, 126.5, 125.9, 122.6, 114.5,
71.0, 70.6, 70.2, 69.8, 58.6, 57.0, 56.8, 50.3, 47.5, 43.2, 41.1, 39.9, 36.1,
35.3, 26.4, 23.1, 21.3, 16.1. HRMS m/z calcd for C57H71ClN7O10S [M
+ H+] 1080.4666, found 1080.4623.
B. Biology. HeLa cells were kept in DMEM medium (Gibco)
supplemented with 10% fetal bovine serum (FBS) (Gibco), L-
glutamine (Gibco), penicillin, streptomycin. MV4;11 and HL60 cells
were kept in RPMI medium (Gibco) supplemented with 10% FBS, L-
glutamine, penicillin, and streptomycin. Cells were kept at 37 °C, 5%
CO2.
Testing Compounds in Cells. HeLa cells were seeded at 3 × 105
per well on a standard 6-well plate. After a day, cells were treated with
compounds for the desired time. Cells were washed with PBS twice
and lysed with RIPA buﬀer (Sigma), supplemented with protease
inhibitor cocktail (Roche), Benzonase (Merck), and 0.5 mM MgCl2.
Lysate was brieﬂy sonicated and centrifuged at 20 000g for 10 min at 4
°C. Supernatant was collected and protein concentration measured by
BCA assay. For MV4;11 and HL60, 1.2 × 107 cells in 15 mL of
medium were treated with compound for the desired time. Cells were
washed with PBS twice and lysed with hypotonic buﬀer (10 mM
HEPES, 10 mM KCl, protease inhibitor cocktail, Benzonase, and 0.5
mM MgCl2) for 30 min by vortexing twice between the incubation
period to disrupt cell outer membrane and release nuclei. Nuclei were
pelleted by centrifugation at 2000g for 15 min. The pellet was
resuspended in RIPA buﬀer, supplemented with protease inhibitor
cocktail, Benzonase, and 0.5 mM MgCl2. The suspension was brieﬂy
sonicated and centrifuged at 20 000g for 10 min at 4 °C. Supernatant
was collected and protein concentration measured by BCA assay.
Immunoblotting. Protein on gel was transferred to nitrocellulose
membrane using iBlot2 (Life Technology) according to manufacturer
guidelines. Blots were probed with anti-Brd4 (AbCam, ab128874),
anti-Brd3 (AbCam, ab50818), anti-Brd2 (AbCam, ab139690), anti-β-
actin (Cell Signaling, no. 4970), anti-cMyc (AbCam, ab32072), anti-
lamin B1 (AbCam, ab133741) antibodies. Blots were developed with
secondary anti-mouse IgG (Licor, 926-32210) or anti-rabbit IgG
(Licor, 926-32213) antibodies from Licor and bands visualized using
Licor Odessey Sa imaging system.
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Western Blot Quantiﬁcation. Image processing and band
intensity quantiﬁcation were performed using Licor Image Studio
software version 5.2.5. Reported band intensities are normalized to
loading control, i.e., β-actin for total lysates and lamin B1 for nuclear
extracts. DC50 values were determined by assuming a linear model
between the two data points across the 50% protein level mark. Dmax
was determined as the highest protein depletion across the
concentrations tested.
Cell Viability Assay. MV4;11 or HL60 cells were incubated with
compounds at the desired concentration for 48 h on a clear-bottom
384-well plate. Cells were kept in RPMI medium supplemented with
10% FBS, L-glutamine, penicillin, and streptomycin. Initial cell density
was 3 × 105 per mL. Cells were treated with various concentrations of
compound or 0.05% DMSO. After treatment, cell viability was
measured with Promega CellTiter-Glo luminescent cell viability assay
kit according to the manufacturer instructions. Signal was recorded on
a BMG Labtech Pherastar luminescence plate reader with recom-
mended settings. Data were analyzed with Graphpad Prism software to
obtain EC50 values of each test compound.
Protein Expression and Puriﬁcation. Bromodomain and VCB
complex constructs and protein preparation were described in a
previous publication.5 Wild-type version of human proteins VHL
(UniProt accession number P40337), ElonginC (Q15369), ElonginB
(Q15370), and the bromodomains of Brd2 (P25440), Brd3 (Q15059),
and Brd4 (O60885) were used for all protein expression. In brief, the
His6-tagged constructs were transformed into E. coli BL21(DE3) and
induced with IPTG to produce the desired proteins. E. coli cells were
homogenized at 4 °C, and His6-tagged proteins were puriﬁed from the
soluble lysate by passing through a Ni aﬃnity column. After cleaving
the His-tag by TEV protease, a second Ni aﬃnity column puriﬁcation
was performed to obtain tag-free protein in the ﬂow-through. VCB was
then additionally puriﬁed by anion exchange using MonoQ (GE
Healthcare). For all proteins, purity was further polished by gel
ﬁltration chromatography.
Isothermal Titration Calorimetry (ITC). Titrations were
performed on an ITC200 microcalorimeter (GE Healthcare) as
previously reported.5 The titrations were in ITC buﬀer (20 mM Bis-
Tris propane, 150 mM NaCl, 1 mM tris(2-carboxyethyl)phosphine
(TCEP), pH 7.4), supplemented with either 0.2% or 3% DMSO and
consisted of 19 injections of 2 μL of protein solution at a rate of 0.5
μL/s at 120 s time intervals. An initial injection of protein (0.4 μL)
was made and discarded during data analysis. All experiments were
performed at 25 °C, while stirring at 600 rpm. PROTACs were diluted
from a 10 mM DMSO stock solution to 20 μM in ITC buﬀer with the
ﬁnal concentration of DMSO to be 0.2% for triazolodiazepine-based
PROTAC or 3% for tetrahydroquinoline-based PROTAC. Bromodo-
main protein in the same buﬀer was titrated into the PROTAC in the
cell. At the end of the titration, the excess of solution was removed
from the cell, the syringe was washed and dried, and VCB complex
(168 μM, in the same buﬀer) was loaded in the syringe and titrated
into the complex of PROTAC−bromodomain. The concentration of
the complex in the cell (C) after the ﬁrst titration (16.8 μM) was
calculated as follows:
=
+
C
C V
V V
0 cell
cell inj
where C0 is the initial concentration of the PROTAC in the cell (20
μM), Vcell is the volume of the sample cell (200.12 μL), and Vinj is the
volume of titrant injected during the ﬁrst titration (38.4 μL).
Titrations for the binary complex PROTAC−VCB were performed
in the same manner with VCB titrated into 16.8 μM PROTAC in the
cell. For titration with 8 and 9, concentrations of PROTAC and
proteins were halved due to compound solubility. The data were ﬁtted
to a single-binding-site model to obtain the stoichiometry n, the
dissociation constant Kd, and the enthalpy of binding ΔH using the
Microcal LLC ITC200 Origin software provided by the manufacturer.
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